首页> 美国卫生研究院文献>other >Long-Term Prognostic Impact of the Use of Erythropoietic-Stimulating Agents in Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Imatinib

【2h】

Long-Term Prognostic Impact of the Use of Erythropoietic-Stimulating Agents in Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Imatinib

机译：用伊马替尼治疗慢性骨髓白血病慢性骨髓白血病患者使用促红细胞刺激剂的长期预后影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUNDAnemia is a frequent side effect of imatinib in patients with chronic myeloid leukemia (CML). Erythropoietic-stimulating agents have been used for treatment of imatinib-induced anemia. There are no data on long-term safety of erythropoietic-stimulating agents in CML patients.

著录项

期刊名称 other
作者
Fabio P. S. Santos; Yesid Alvarado; Hagop Kantarjian; Dushyant Verma; Susan O’Brien; Gloria Mattiuzzi; Farhad Ravandi; Gautam Borthakur; Jorge Cortes;
展开▼
作者单位

展开▼
年(卷),期 -1(117),5
年度 -1
页码 982–991
总页数 18
原文格式 PDF
正文语种
中图分类
关键词
chronic myeloid leukemia imatinib anemia erythropoiesis-stimulating agents tyrosine kinase inhibitors;

机译：慢性粒细胞白血病;伊马替尼;贫血;促红细胞生成剂;酪氨酸激酶抑制剂;

相似文献

外文文献
中文文献
专利

1. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib? [J] . Fabio P. S. Santos MD, Yesid Alvarado MD Hagop Kantarjian MD, Gautam Borthakur MD Jorge Cortes MD, Cancer . 2011,第5期

机译：伊马替尼？治疗对慢性粒细胞白血病慢性期患者使用促红细胞生成剂的长期预后影响
2. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70. [J] . Doggrell SA, Christensen AM Expert opinion on pharmacotherapy . 2011,第1期

机译：是否有比伊马替尼更好的Bcr-Abl激酶抑制剂用于慢性粒细胞白血病？ Saglio G，Kim D-W，Issaragrisil S等的评估。尼洛替尼与伊马替尼治疗新诊断的慢性粒细胞白血病。 N Engl J Med 2010; 362：2251-9，and Kantarjian H，Shah NP，Hochhaus A等。达沙替尼与伊马替尼治疗新近诊断的慢性期慢性粒细胞白血病。 N Engl J Med 2010; 362：2260-70。
3. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate [J] . Cancer genetics . 2012,第11期

机译：甲磺酸伊马替尼治疗的新诊断的慢性期慢性粒细胞白血病患者克隆染色体异常的长期临床意义
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Myeloid Neoplasia: A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib [O] . Shannon K. McWeeney, Lucy C. Pemberton, Marc M. Loriaux, -1

机译：髓样瘤形成：CD34 +细胞的基因表达特征可预测接受伊马替尼治疗的慢性期慢性髓样白血病患者的主要细胞遗传学反应
7. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria [O] . Branford, S., Seymour, J., Grigg, A., 2007

机译：用伊马替尼治疗的慢性粒细胞白血病患者BCR-aBL信使RNa水平继续下降超过5年，并且使用严格的敏感性标准，大约一半的一线治疗患者具有稳定的不可检测的BCR-aBL

Long-Term Prognostic Impact of the Use of Erythropoietic-Stimulating Agents in Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Imatinib

摘要

著录项

相似文献

相关主题

期刊订阅